Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD

被引:24
作者
Hermans, Michel P. [1 ]
机构
[1] Clin Univ St Luc, Brussels, Belgium
关键词
diabetic complications; fenofibrate; microvascular disease; type; 2; diabetes; CARDIOVASCULAR-DISEASE; TYPE-2; INTERVENTION; ASSOCIATION; PREVALENCE; EXPRESSION; OUTCOMES; THERAPY; EVENTS; ALPHA;
D O I
10.1177/1479164111407783
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Microvascular complications are common in type 2 diabetes in primary care. Intensified management of glycaemia or blood pressure had little effect on microvascular complication rates in recent large trials (ADVANCE, VADT, ACCORD). In 2005, the FIELD study demonstrated a significant reduction in the need for laser treatment for retinopathy, and of progression of renal dysfunction, with fenofibrate versus placebo. The FIELD ophthalmology sub-study showed that fenofibrate reduced the risk of new retinopathy and progression of retinopathy. Also, fenofibrate versus placebo significantly reduced the risk of non-traumatic, diabetes-related amputations in a post-hoc analysis from FIELD. Recently, the results of the ACCORD Lipid study were consistent with these findings, as fenofibrate significantly reduced progression of retinopathy and albuminuria, apparently independent of effects on lipids. These findings suggest a role for fenofibrate in the prevention of major diabetic microvascular complications.
引用
收藏
页码:180 / 189
页数:10
相关论文
共 43 条
[1]  
*ABB INC, TRICOR FEN TABL PRES
[2]  
Abdul-Ghani M, 2006, ISR MED ASSOC J, V8, P378
[3]  
Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[4]  
[Anonymous], 2005, Global guideline for Type 2 diabetes
[5]   Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications [J].
Ayad, F. ;
Belhadj, M. ;
Paries, J. ;
Attali, J. R. ;
Valensi, P. .
DIABETIC MEDICINE, 2010, 27 (07) :804-811
[6]   Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [J].
Burgess, David C. ;
Hunt, David ;
Li, LiPing ;
Zannino, Diana ;
Williamson, Elizabeth ;
Davis, Timothy M. E. ;
Laakso, Markku ;
Kesaniemi, Y. Antero ;
Zhang, Jun ;
Sy, Raymond W. ;
Lehto, Seppo ;
Mann, Stewart ;
Keech, Anthony C. .
EUROPEAN HEART JOURNAL, 2010, 31 (01) :92-99
[7]   Systematic approach for the management of chronic kidney disease: moving beyond chronic kidney disease classification [J].
Burgos-Calderon, Rafael ;
Depine, Santos .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2010, 19 (02) :208-213
[8]  
Cheung N, 2008, LANCET, V371, P721, DOI 10.1016/S0140-6736(08)60333-5
[9]   Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus [J].
Cushman, William C. ;
Evans, Gregory W. ;
Byington, Robert P. ;
Goff, David C., Jr. ;
Grimm, Richard H., Jr. ;
Cutler, Jeffrey A. ;
Simons-Morton, Denise G. ;
Basile, Jan N. ;
Corson, Marshall A. ;
Probstfield, Jeffrey L. ;
Katz, Lois ;
Peterson, Kevin A. ;
Friedewald, William T. ;
Buse, John B. ;
Bigger, J. Thomas ;
Gerstein, Hertzel C. ;
Ismail-Beigi, Faramarz .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (17) :1575-1585
[10]   Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study [J].
Davis, T. M. E. ;
Ting, R. ;
Best, J. D. ;
Donoghoe, M. W. ;
Drury, P. L. ;
Sullivan, D. R. ;
Jenkins, A. J. ;
O'Connell, R. L. ;
Whiting, M. J. ;
Glasziou, P. P. ;
Simes, R. J. ;
Kesaniemi, Y. A. ;
Gebski, V. J. ;
Scott, R. S. ;
Keech, A. C. .
DIABETOLOGIA, 2011, 54 (02) :280-290